Received April 29, 2005; revision received June 20, 2005; accepted July 12, 2005. From the Department of Psychiatry and Behavioral Sciences, the Department of Pathology and Laboratory Medicine, and the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta; and the Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston. Address correspondence and reprint requests to Dr. Stowe, Emory Women’s Mental Health Program, 1365 Clifton Rd., N.E., Suite B6100, Atlanta, GA 30322; email@example.com (e-mail). Supported by an unrestricted educational grant from Pfizer Pharmaceuticals, a research grant from GlaxoSmithKline (GSK), and an NIMH Specialized Center of Research grant (P50 MH-68036). The authors thank Lilly, Pfizer, GSK, and Wyeth for providing appropriate internal standards for determination of metabolite concentrations, the Atlanta community obstetricians who collected these samples, and the women who willingly participated in this study. Disclosure of competing interests: Dr. Newport is on the speakers’ bureau for GSK and Eli Lilly. Dr. Owens is a consultant for Bristol-Myers Squibb, Cielo Institute, Cypress Biosciences, and Pfizer; is on the speakers’ bureau for Forest Labs, GSK, Pfizer, and Lundbeck; and receives research support from Pfizer, GSK, Merck, and UCB Pharma. Dr. DeVane is on the speakers’ bureau for GSK, Bristol-Myers Squibb, Janssen, and AstraZeneca and the advisory board for GSK, Sommerset, and Eli Lilly. Dr. Stowe is on the speakers’ bureau for Pfizer, Wyeth, GlaxoSmithKline, and Eli Lilly and on the advisory board for GSK. See the online version of this article for supplemental data.